Professional Marketing: Novartis, Epocrates, Cegedim Dendrite and SK&A Information Services

Share this article:
Novartis launched schizophrenia med Fanapt to US physicians, following a May 2009 approval. In October, Novartis acquired US and Canadian commercialization rights to the pill from Vanda, which retains ex-US marketing rights. A long-acting injectable (depot) formulation is being developed.

Mobile clinical-software outfit Epocrates hired Geoffrey Rutledge, MD, PhD, as chief medical officer and EVP, product development. Rutledge, who has held senior-management roles with WebMD and First Consulting Group, will oversee Epocrates' medical-information team and lead the development of new products.

CRM firm Cegedim Dendrite acquired healthcare data provider SK&A Information Services for an undisclosed sum. SK&A maintains a telephone-verifiable database of contact records used by pharma clients for commercial planning and operations. The firm will be branded as SK&A, A Cegedim Company.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.